抗体成药性筛选流程及评价策略

自1986年OKT3作为第一个治疗性单克隆抗体获批上市后,抗体技术及抗体药物迅猛发展。单克隆抗体、抗体片段、双(多)特异性抗体、融合蛋白、纳米抗体以及抗体偶联药物(antibody-drug conjugates, ADCs)等推陈出新,在肿瘤、血液、免疫、呼吸和代谢等相关疾病的治疗领域发挥着举足轻重的作用。抗体药物的发现过程,是通过多轮生物学功能评估和可成药性评估,筛选出具有安全、有效、稳定和可工艺放大的最佳候选序列,从而提高药物开发和临床研究的效率及成功率。抗体药物发现阶段的“成药性筛选与评估”已日益受到关注和重视,从药物发现和设计、先导分子筛选到候选分子确认,可及时发现分子潜在的物理化学风险因素,并评估可控性,保证后续药物开发过程中的质量稳定性。本文对抗体发现阶段的成药性筛选评估流程进行了分类和定义,涉及单克隆抗体、双特异性抗体、纳米抗体和ADCs等相关技术和药物形式,同时总结了成药性筛选评估中应重点关注的质量属性和高通量检测技术;系统性地阐述成药性开发流程和策略,为不断涌现的创新型药物的成药性筛选评估提供参考,大幅提高抗体药物开发的效率和成功率。     

生物大分子从头合成和设计的研究进展

生物大分子指生物体内存在的DNA、蛋白质、多糖等物质,其对生物体正常生命活动至关重要.从头合成和设计技术在生物大分子的合成和结构设计上具有自由度高、前体简单等特点,能够按照特定研究目的对生物大分子进行全新设计和高效合成.近年来,从头合成与设计技术在人造基因组合成、新型蛋白质类药物设计、糖缀合物合成等领域已开始受到重视.基于生物大分子从头合成和设计技术,可以定向制备全新设计的DNA或全新的基因表达产物,以及具有识别功能的糖链或糖缀合物,将大大推进诸如细胞因子模拟物、基因治疗递送载体等生物活性物质的开发,为人工生物系统的构建、罕见疾病的治疗等提供新的解决方法.本文就DNA、蛋白质和多糖的从头合成和设计进行了综述,阐述了相关方法及应用,最后概括分析了三者之间的关系.     

细胞穿透肽:一种新型非病毒载体

细胞膜的选择通透性对维持细胞内环境的稳定起着非常重要的作用,但细胞膜的这种特性限制了一些生物大分子和药物进入细胞内,不利于对一些细胞内疾病的诊断和药物靶向治疗的应用。如何将一些具有诊断和治疗潜力的生物大分子、药物通过细胞膜进入细胞内一直是医学界研究的热点和难点。细胞穿透肽是一类能够携带多肽、蛋白质、核酸、纳米颗粒、病毒颗粒及药物等穿过细胞膜进入细胞,导致完整载物内化的短肽,为生物大分子和药物进入细胞内部提供了有力的运载工具,其作为载体具有的高转导效率和低毒性特点,已经得到了广泛关注和大量研究。目前,细胞穿透肽作为生物分子和药物细胞内化的运载体已经在荧光成像,肿瘤治疗,抗炎治疗及药物靶向治疗中发挥了潜在的诊断和治疗作用,显示出其诱人的应用前景。     

微针用于生物大分子及纳米药物透皮给药的尝试与挑战

生物大分子及纳米药物,比如,亚单位疫苗、DNA疫苗、以及针对真皮层的治疗药物,作为近年来新兴的治疗药物,在有些治疗领域有着透皮给药的需求。由于具有靶向性高,疗效显著等特点,生物大分子及纳米药物逐渐成为新的研究热点。微针作为一种新型的给药技术,不仅具有无痛、给药方便等优点,而且运用物理手段可大幅提高大分子甚至纳米药物的透皮吸收及皮层靶向,能够避过胃肠道消化作用以及肝脏首过效用。将微针技术与生物大分子药物相结合,能够同时发挥两者的优势,实现高靶向生物药物的无痛给药。本文简述微针透皮给药技术、以及生物大分子给药的研究进展,对微针技术用于生物大分子及纳米药物透皮给药的尝试研究做了介绍和总结,对存在的技术挑战进行了分析和展望。     

细胞穿透肽在肿瘤治疗中的应用

随着人类对基因组信息解读的不断深入,越来越多的生物大分子作为候选药物进入生物治疗领域。但细胞表面的脂质双层膜具有选择通透性,这种天然屏障作用在保护细胞的同时也限制了绝大多数生物大分子进入细胞内部发挥治疗效应。目前流行的入胞转运方式如电穿孔、脂质体转染等均存在对细胞的额外毒副作用,且作用范围局限于体外实验。细胞穿透肽是一类以非受体依赖方式,非经典内吞方式直接穿过细胞膜进入细胞的多肽。它们可以与多种生物活性物质连接并携带其进入细胞,这一特性为它们成为理想的药物载体提供了可能。本文对使用细胞穿透肽作为载体转运具有抗癌作用的生物大分子进入细胞的抗癌实验予以介绍。     

生物可降解聚合物纳米粒给药载体

生物可降解聚合物纳米粒用于给药载体具有广阔的前景。本文综述了生物可降解聚合物纳米粒给药载体领域的最新进展 :包括纳米粒表面修饰特性、药物释放、载多肽和蛋白质等生物大分子药物传输中的潜在应用。     

生物电子等排原理在药物先导化合物优化中的应用

先导化合物的优化是新药研究和开发的重要环节。由于先导化合物只提供一种具有特定药理作用的新结构类型,往往由于在药理、药效学、药代动力学等方面的缺点或不足而不能直接用于临床。因此,需要对先导化合物进行进一步化学结构改造或修饰,以期优化上述特性。“生物电子等排取代(bioisostericreplacement)”即为对先导化合物进行合理优化的有效策略之一。本文简要综述了生物电子等排原理在药物先导化合物优化中的应用。     

海藻酸钠壳聚糖微球作为药物载体的研究进展

海藻酸钠壳聚糖微球是具有生物粘附性且能结合和传递大分子药物的天然高分子材料,且在生物医学领域具有广阔应用前景的药物载体。它具有生物黏附性、生物相容性、生物可降解性、对人体无毒性且能够结合和传递大分子药物的天然高分子材料。海藻酸钠壳聚糖微球作为载药微球具有提高药物的生物利用度、延长药物的作用时间等优点。国内外近些年已将其应用于药剂学领域,以及将其作为药物载体经微球化与药物结合形成给药系统的研究也在逐步开展并取得了较多成果。本文主要阐述海藻酸钠壳聚糖微球的主要生物特性、作用特点及其在医学领域中应用的研究进展,并对其应用前景进行探讨。     

壳聚糖作为药物缓释控释载体的研究进展

壳聚糖因其具有良好的生物学特性而成为多种药物载体研究的热点。药物经过壳聚糖负载后,不仅能够达到缓释控释的目的,还能够改变药物的给药方式,以此减少给药次数,降低药物不良反应,提高药物生物利用度。本文就壳聚糖和改性壳聚糖作为普通药物和生物大分子药物载体的研究进展作一综述。     

金属有机骨架在肿瘤治疗中的应用进展

金属有机骨架(metal-organic frameworks,MOFs)是一类由金属结点和有机配体配位组装而成的晶体材料.金属有机骨架具有孔隙度大、孔径和尺寸可调、生物相容性好、成分可调、表面可修饰等优越性能,在肿瘤治疗领域具有重要的应用潜力.本文首先介绍了金属有机骨架用于小分子药物、生物大分子药物等药物递送体系的构建方法.随后,我们总结了近年来MOFs药物递送体系在肿瘤的化学治疗、光动力学治疗、放射性治疗、免疫治疗、光热治疗等方面的应用进展.最后,本文总结了MOFs在肿瘤治疗方面的进展和特点,并展望了MOFs在肿瘤治疗领域的研究挑战和应用前景.     

The past and future of structure databases

For many years the primary source of information about biological macromolecules was the Protein Data Bank, which is a repository of files containing coordinates of biological macromolecules. Now a variety of databases has been developed in which structures are organized in different ways. Currently available are databases that classify molecules according to their overall structural characteristics or particular features of structures, as well as databases that focus on particular protein families in depth.     

极地微生物 —— 新天然药物的潜在来源

微生物是极地生态系统的重要组成部分.由于极地独特的地理、气候及环境特点,极地微生物所具有的新颖性与多样性,在科学研究、应用开发等方面都具有重要价值,并逐渐受到人们的广泛关注.有关极地微生物的资源勘探与代谢活性产物研究,已成为国际微生物学研究的热点之一.结合笔者的工作实践,对近年来极地微生物资源的勘探与收集情况进行了介绍,并着重对以医药与生物农药等为目标的极地微生物产活性化合物的研究现状进行了概述,同时还对目前一些影响研究工作开展的限制因素进行了讨论.可以预见,针对极地微生物资源的研究开发工作,将会给新型天然药物的筛选与发现带来新的机遇与突破.     

质谱和核磁共振成为研究生物大分子的重要方法 ———简介2002年诺贝尔化学奖得主的贡献

2002年诺贝尔化学奖授予了在质谱和核磁共振领域有杰出贡献的三位科学家。Jonh B. Fenn和Koichi Tanaka发展了质谱鉴定生物大分子质量的方法,Kurt Wuethrich建立了核磁共振测定蛋白质分子溶液三维结构的方法。他们的研究成果是质谱和核磁共振方法发展的里程碑,极大地推动了这两种研究方法的进一步发展。如今,质谱和核磁共振已发展成为认识生物大分子的强劲的研究手段。     

Phytosterols and triterpenes from Morinda lucida Benth (Rubiaceae) as potential inhibitors of anti-apoptotic BCL-XL,BCL-2, and MCL-1: an in-silico study

Deregulation of the normal cellular apoptotic function is a fundamental element in the etiology of most cancers and the anti-apoptotic B cell lymphoma 2 (BCL?2) protein family is known to play crucial role in the regulation of this function. Overexpression of this protein family has been implicated in some cancers, such that agents that could inhibit their over-activity are now being explored for anticancer drug development. A number of studies have revealed the anticancer potential of Morinda lucida-derived extracts and compounds. In search of more inhibitors of this anti-apoptotic protein family from plant resources, 47 compounds, identified in Morinda lucida Benth (Rubiaceae) were screened for their inhibitory activities against BCL-XL, BCL-2, and MCL-1 by molecular docking using BINDSURF, while binding interactions of the top compounds were viewed with PyMOL. Druglikeness and Absorption–Distribution–Metabolism–Excretion (ADME) parameters of the top 6 compounds from docking study were evaluated using SuperPred webserver. Results revealed that out of the 47 compounds, 2 triterpenes (ursolic acid and oleanolic acid) and 4 phytosterols (cycloartenol, campesterol, stigmasterol, and β-sitosterol) have higher binding affinities for the selected BCL-2 proteins, compared to known standard inhibitors; these compounds also fulfill oral drugability of Lipinski rule of five. Therefore, since these Morinda lucida-derived phytosterols and triterpenes show high binding affinity toward the selected anti-apoptotic proteins and exhibited good drugability characteristics, they qualify for further study on drug development against cancers characterized by overexpression of this family of protein.     

Origin of low-frequency motions in biological macromolecules. A view of recent progress in the quasi-continuity model

The recent progress in the quasi-continuity model and its applications in studying the low-frequency internal motions of biological macromolecules have been surveyed. Emphasis is placed on revealing the origin of this kind of internal collective motion, which involves many atoms and has significant biological functions. In light of such a line, the low-frequency motions in alpha-helix structure, beta-structure (including beta-sheet and beta-barrel), and DNA double-helix structure, the three most fundamental component elements in biological macromolecules, are discussed, and the corresponding physical pictures described. It turns out that the low-frequency motion in biological macromolecules originates from their two common intrinsic characteristics, i.e., they possess a series of weak bonds, such as hydrogen bonds and salt bridges, and a substantial mass distributed over the region containing those weak bonds.     

真核细胞质膜蛋白质组研究进展

细胞膜（质膜）蛋白质是细胞的“门铃”与“门户”,是许多药物的作用靶标。细胞质膜蛋白质组的研究正成为蛋白质组研究的热点,这方面的研究有利于具有重要功能的低丰度蛋白质的发掘,为药物研发和疾病的诊断提供靶体与标记蛋白质。然而,质膜蛋白质组的研究在强疏水性跨膜蛋白质和低丰度膜蛋白质的分离和鉴定上遇到了方法学的挑战。本文对质膜及其微区的纯化、质膜蛋白质组的分离与鉴定、生物信息学,以及亚细胞定位研究的近期进展作扼要介绍。     

Salicylhydroxamic Acid Functionalized Affinity Membranes for Specific Immobilization of Proteins and Oligonucleotides

Immobilization of proteins and other biological macromolecules on solid supports is a method suitable for purification or screening applications in life science research. Prolinx, Inc. has developed a novel chemical affinity system that can be used for specific immobilization of proteins and other macromolecules via interaction of two small synthetic molecules, phenyldiboronic acid (PDBA) and salicylhydroxamic acid (SHA). This report describes immobilization applications of activated microporous membranes that have been functionalized with SHA derivatives. These SHA-membranes exhibit high capacity and specificity for binding of PDBA-labeled nucleic acids and proteins. Conjugation of active protein with PDBA is performed in solution independent of the immobilization step on SHA membranes. The resulting PDBA–protein conjugate is immobilized directly without purification and retains biological activity. PDBA conjugates may also be released from these SHA-affinity membranes in a controlled manner. Capture and release of PBA-modified oligonucleotides is also demonstrated. SHA-membranes can be used as surfaces for microarrays, and are therefore compatible with high-throughput analyses. These properties make them useful for development of numerous preparative or screening applications.     

History and perspectives of bioanalytical methods for chemical warfare agent detection

This paper provides a short historical overview of the development of bioanalytical methods for chemical warfare (CW) agents and their biological markers of exposure, with a more detailed overview of methods for organophosphorus nerve agents. Bioanalytical methods for unchanged CW agents are used primarily for toxicokinetic/toxicodynamic studies. An important aspect of nerve agent toxicokinetics is the different biological activity and detoxification pathways for enantiomers. CW agents have a relatively short lifetime in the human body, and are hydrolysed, metabolised, or adducted to nucleophilic sites on macromolecules such as proteins and DNA. These provide biological markers of exposure. In the past two decades, metabolites, protein adducts of nerve agents, vesicants and phosgene, and DNA adducts of sulfur and nitrogen mustards, have been identified and characterized. Sensitive analytical methods have been developed for their detection, based mainly on mass spectrometry combined with gas or liquid chromatography. Biological markers for sarin, VX and sulfur mustard have been validated in cases of accidental and deliberate human exposures. The concern for terrorist use of CW agents has stimulated the development of higher throughput analytical methods in support of homeland security.